Oral immunotherapy for peanut allergy: The pro argument
Food allergy (FA) is a growing public health problem with personal, social, nutritional, and economic consequences. In the United States, it is estimated that 8% of children and 10.8% of adults have food allergies. Allergies to peanuts are particularly worrisome as unlike allergies to other allergen...
Saved in:
| Published in: | The World Allergy Organization journal Vol. 13; no. 8; p. 100455 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Elsevier Inc
01.08.2020
World Allergy Organization Elsevier |
| Subjects: | |
| ISSN: | 1939-4551, 1939-4551 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Food allergy (FA) is a growing public health problem with personal, social, nutritional, and economic consequences. In the United States, it is estimated that 8% of children and 10.8% of adults have food allergies. Allergies to peanuts are particularly worrisome as unlike allergies to other allergenic foods, such as milk and egg, which are commonly outgrown by 5 or 10 years of age, 80% of peanut allergies persist into adulthood. The first drug for peanut allergy, Palforzia, was approved by the US Food and Drug Administration (FDA) in January 2020. For other food allergies, the current standard of care for the management of FA is suboptimal and is limited to dietary elimination of the offending allergen, vigilance against accidental ingestion, and treatment of allergic reactions with antihistamines and epinephrine. However, dietary avoidance can be challenging, and it is estimated that approximately 40% of patients with food allergies report at least one food allergy-related emergency department in their lifetime. Reactions, even from minimal exposures, can be life-threatening.
Oral immunotherapy (OIT) has been the best researched therapeutic approach for treating FA over the last decade, with clinical trials investigating its efficacy, safety, and ability to improve participants' quality of life (QoL). A number of studies and meta-analyses have shown that OIT treatment is effective in raising the threshold of reactivity to peanuts and other foods in addition to producing a measurable serum immune response to such therapy. Although OIT-related adverse events (AEs) are common during treatment, serious reactions are rare. In fact, while the majority of patients experience AEs related to dosing, most continue daily dosing in hopes of achieving protection against the culprit food. Moreover, the majority of participants report improvement of QoL after OIT and are positive about undergoing OIT. These results show patients’ commitment to OIT and their optimism regarding the benefits of treatment. As a first step in therapeutic options to protect from reactions to unintentional ingestion of allergenic foods, and importantly, to address the many psychosocial aspects of living with FA, OIT shows promise. Future research will focus on identifying optimal OIT regimens that maintain protection after therapy and allow for regular food consumption without allergic symptoms. Education and informed shared decision making between patients and providers are essential in optimizing current therapy regimens. |
|---|---|
| AbstractList | Food allergy (FA) is a growing public health problem with personal, social, nutritional, and economic consequences. In the United States, it is estimated that 8% of children and 10.8% of adults have food allergies. Allergies to peanuts are particularly worrisome as unlike allergies to other allergenic foods, such as milk and egg, which are commonly outgrown by 5 or 10 years of age, 80% of peanut allergies persist into adulthood. The first drug for peanut allergy, Palforzia, was approved by the US Food and Drug Administration (FDA) in January 2020. For other food allergies, the current standard of care for the management of FA is suboptimal and is limited to dietary elimination of the offending allergen, vigilance against accidental ingestion, and treatment of allergic reactions with antihistamines and epinephrine. However, dietary avoidance can be challenging, and it is estimated that approximately 40% of patients with food allergies report at least one food allergy-related emergency department in their lifetime. Reactions, even from minimal exposures, can be life-threatening. Oral immunotherapy (OIT) has been the best researched therapeutic approach for treating FA over the last decade, with clinical trials investigating its efficacy, safety, and ability to improve participants' quality of life (QoL). A number of studies and meta-analyses have shown that OIT treatment is effective in raising the threshold of reactivity to peanuts and other foods in addition to producing a measurable serum immune response to such therapy. Although OIT-related adverse events (AEs) are common during treatment, serious reactions are rare. In fact, while the majority of patients experience AEs related to dosing, most continue daily dosing in hopes of achieving protection against the culprit food. Moreover, the majority of participants report improvement of QoL after OIT and are positive about undergoing OIT. These results show patients' commitment to OIT and their optimism regarding the benefits of treatment. As a first step in therapeutic options to protect from reactions to unintentional ingestion of allergenic foods, and importantly, to address the many psychosocial aspects of living with FA, OIT shows promise. Future research will focus on identifying optimal OIT regimens that maintain protection after therapy and allow for regular food consumption without allergic symptoms. Education and informed shared decision making between patients and providers are essential in optimizing current therapy regimens.Food allergy (FA) is a growing public health problem with personal, social, nutritional, and economic consequences. In the United States, it is estimated that 8% of children and 10.8% of adults have food allergies. Allergies to peanuts are particularly worrisome as unlike allergies to other allergenic foods, such as milk and egg, which are commonly outgrown by 5 or 10 years of age, 80% of peanut allergies persist into adulthood. The first drug for peanut allergy, Palforzia, was approved by the US Food and Drug Administration (FDA) in January 2020. For other food allergies, the current standard of care for the management of FA is suboptimal and is limited to dietary elimination of the offending allergen, vigilance against accidental ingestion, and treatment of allergic reactions with antihistamines and epinephrine. However, dietary avoidance can be challenging, and it is estimated that approximately 40% of patients with food allergies report at least one food allergy-related emergency department in their lifetime. Reactions, even from minimal exposures, can be life-threatening. Oral immunotherapy (OIT) has been the best researched therapeutic approach for treating FA over the last decade, with clinical trials investigating its efficacy, safety, and ability to improve participants' quality of life (QoL). A number of studies and meta-analyses have shown that OIT treatment is effective in raising the threshold of reactivity to peanuts and other foods in addition to producing a measurable serum immune response to such therapy. Although OIT-related adverse events (AEs) are common during treatment, serious reactions are rare. In fact, while the majority of patients experience AEs related to dosing, most continue daily dosing in hopes of achieving protection against the culprit food. Moreover, the majority of participants report improvement of QoL after OIT and are positive about undergoing OIT. These results show patients' commitment to OIT and their optimism regarding the benefits of treatment. As a first step in therapeutic options to protect from reactions to unintentional ingestion of allergenic foods, and importantly, to address the many psychosocial aspects of living with FA, OIT shows promise. Future research will focus on identifying optimal OIT regimens that maintain protection after therapy and allow for regular food consumption without allergic symptoms. Education and informed shared decision making between patients and providers are essential in optimizing current therapy regimens. Food allergy (FA) is a growing public health problem with personal, social, nutritional, and economic consequences. In the United States, it is estimated that 8% of children and 10.8% of adults have food allergies. Allergies to peanuts are particularly worrisome as unlike allergies to other allergenic foods, such as milk and egg, which are commonly outgrown by 5 or 10 years of age, 80% of peanut allergies persist into adulthood. The first drug for peanut allergy, Palforzia, was approved by the US Food and Drug Administration (FDA) in January 2020. For other food allergies, the current standard of care for the management of FA is suboptimal and is limited to dietary elimination of the offending allergen, vigilance against accidental ingestion, and treatment of allergic reactions with antihistamines and epinephrine. However, dietary avoidance can be challenging, and it is estimated that approximately 40% of patients with food allergies report at least one food allergy-related emergency department in their lifetime. Reactions, even from minimal exposures, can be life-threatening. Oral immunotherapy (OIT) has been the best researched therapeutic approach for treating FA over the last decade, with clinical trials investigating its efficacy, safety, and ability to improve participants' quality of life (QoL). A number of studies and meta-analyses have shown that OIT treatment is effective in raising the threshold of reactivity to peanuts and other foods in addition to producing a measurable serum immune response to such therapy. Although OIT-related adverse events (AEs) are common during treatment, serious reactions are rare. In fact, while the majority of patients experience AEs related to dosing, most continue daily dosing in hopes of achieving protection against the culprit food. Moreover, the majority of participants report improvement of QoL after OIT and are positive about undergoing OIT. These results show patients’ commitment to OIT and their optimism regarding the benefits of treatment. As a first step in therapeutic options to protect from reactions to unintentional ingestion of allergenic foods, and importantly, to address the many psychosocial aspects of living with FA, OIT shows promise. Future research will focus on identifying optimal OIT regimens that maintain protection after therapy and allow for regular food consumption without allergic symptoms. Education and informed shared decision making between patients and providers are essential in optimizing current therapy regimens. Food allergy (FA) is a growing public health problem with personal, social, nutritional, and economic consequences. In the United States, it is estimated that 8% of children and 10.8% of adults have food allergies. Allergies to peanuts are particularly worrisome as unlike allergies to other allergenic foods, such as milk and egg, which are commonly outgrown by 5 or 10 years of age, 80% of peanut allergies persist into adulthood. The first drug for peanut allergy, Palforzia, was approved by the US Food and Drug Administration (FDA) in January 2020. For other food allergies, the current standard of care for the management of FA is suboptimal and is limited to dietary elimination of the offending allergen, vigilance against accidental ingestion, and treatment of allergic reactions with antihistamines and epinephrine. However, dietary avoidance can be challenging, and it is estimated that approximately 40% of patients with food allergies report at least one food allergy-related emergency department in their lifetime. Reactions, even from minimal exposures, can be life-threatening.Oral immunotherapy (OIT) has been the best researched therapeutic approach for treating FA over the last decade, with clinical trials investigating its efficacy, safety, and ability to improve participants' quality of life (QoL). A number of studies and meta-analyses have shown that OIT treatment is effective in raising the threshold of reactivity to peanuts and other foods in addition to producing a measurable serum immune response to such therapy. Although OIT-related adverse events (AEs) are common during treatment, serious reactions are rare. In fact, while the majority of patients experience AEs related to dosing, most continue daily dosing in hopes of achieving protection against the culprit food. Moreover, the majority of participants report improvement of QoL after OIT and are positive about undergoing OIT. These results show patients’ commitment to OIT and their optimism regarding the benefits of treatment. As a first step in therapeutic options to protect from reactions to unintentional ingestion of allergenic foods, and importantly, to address the many psychosocial aspects of living with FA, OIT shows promise. Future research will focus on identifying optimal OIT regimens that maintain protection after therapy and allow for regular food consumption without allergic symptoms. Education and informed shared decision making between patients and providers are essential in optimizing current therapy regimens. |
| ArticleNumber | 100455 |
| Author | Chandra, Sharad Sampath, Vanitha Chinthrajah, R. Sharon Chen, Meng Nadeau, Kari Cao, Shu Dunham, Theresa Sindher, Sayantani |
| Author_xml | – sequence: 1 givenname: R. Sharon surname: Chinthrajah fullname: Chinthrajah, R. Sharon email: schinths@stanford.edu organization: Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, CA, USA – sequence: 2 givenname: Shu surname: Cao fullname: Cao, Shu organization: Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, CA, USA – sequence: 3 givenname: Theresa surname: Dunham fullname: Dunham, Theresa organization: Department of Internal Medicine, Stanford University, Stanford, CA, USA – sequence: 4 givenname: Vanitha surname: Sampath fullname: Sampath, Vanitha organization: Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, CA, USA – sequence: 5 givenname: Sharad surname: Chandra fullname: Chandra, Sharad organization: Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, CA, USA – sequence: 6 givenname: Meng surname: Chen fullname: Chen, Meng organization: Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, CA, USA – sequence: 7 givenname: Sayantani surname: Sindher fullname: Sindher, Sayantani organization: Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, CA, USA – sequence: 8 givenname: Kari surname: Nadeau fullname: Nadeau, Kari organization: Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, CA, USA |
| BookMark | eNqFkU1v3CAQhlGVqvlo_0EPPvayW7DBxlFVqYr6ESlSLukZjWG8i4uNC3ai_ffF9VZqctkTo2HeZ3h5L8nZ4Ack5D2jW0ZZ-bHbPoHv_LzNab60KBfiFblgdVFvUsnO_qvPyWWMHaUlZaJ4Q86LglKRy_KCVPcBXGb7fh78tMcA4yFrfchGhGGeMnAOw-5wnT3sMRuDzyDs5h6H6S153YKL-O54XpGf374-3PzY3N1_v735crfRQtTTxjSVoUYXFDkFI00JvGl5i3VOq1yDMaZupakY0FKaQlYs55RVlNe8lY0UrLgityvXeOjUGGwP4aA8WPW34cNOQZisdqhYI0yuE4UWLUex7ICSyULmJvnWkFifV9Y4Nz0anWwk88-gz28Gu1c7_6gqwRKMJ8CHIyD43zPGSfU2anQOBvRzVDnnkqc02DJ6vY7q4GMM2CptJ5isX8jWKUbVkqLq1JqiWlJUa4pJzF-I_73xhOzoD1MgjxaDitrioNHYgHpKP2ZPAT69AGhnB6vB_cLDafkfTd_NnA |
| CitedBy_id | crossref_primary_10_1016_j_jaip_2022_11_036 crossref_primary_10_1016_j_jaci_2023_08_006 crossref_primary_10_1111_all_15027 crossref_primary_10_3389_fpls_2021_723363 crossref_primary_10_1186_s13223_024_00926_3 crossref_primary_10_1016_j_jaip_2021_08_044 crossref_primary_10_1016_j_humimm_2024_111179 crossref_primary_10_3389_fimmu_2020_603050 crossref_primary_10_3390_foods10051037 crossref_primary_10_1038_s41467_022_34222_8 crossref_primary_10_1080_13543776_2021_1893691 crossref_primary_10_1097_ACI_0000000000000978 crossref_primary_10_1111_all_15659 crossref_primary_10_1016_j_jaip_2020_12_067 crossref_primary_10_1097_ACI_0000000000000742 crossref_primary_10_1016_j_jaip_2021_01_013 crossref_primary_10_1016_j_waojou_2022_100687 crossref_primary_10_1097_ACI_0000000000000781 crossref_primary_10_1186_s13223_025_00948_5 crossref_primary_10_2147_JAA_S282696 |
| Cites_doi | 10.1186/1710-1492-10-25 10.1111/apa.13668 10.1016/j.jaci.2014.11.034 10.3390/ijerph15092043 10.1111/all.13124 10.1111/all.13330 10.1111/j.1365-2222.2011.03699.x 10.1016/j.jaip.2017.09.016 10.1159/000375417 10.1016/j.jaip.2018.06.016 10.1024/0300-9831/a000055 10.1111/j.1398-9995.2007.01421.x 10.1186/s13601-015-0055-x 10.1016/j.jaci.2010.04.030 10.1016/j.jaci.2016.08.010 10.1159/000486310 10.1007/s12016-018-8708-x 10.1111/all.12441 10.1016/j.alit.2017.02.001 10.1016/S0140-6736(13)62301-6 10.1016/j.jaip.2019.04.010 10.1016/j.jaci.2013.09.046 10.1016/j.jaci.2016.05.027 10.1016/j.jaci.2009.03.045 10.1016/j.waojou.2018.11.008 10.1016/j.jaci.2011.10.023 10.1016/j.jaip.2017.05.006 10.1016/j.jaip.2018.10.048 10.1016/S2352-4642(17)30041-X 10.1016/S0140-6736(19)31793-3 10.1016/j.jaci.2009.05.022 10.18176/jiaci.0143 10.1016/j.jaci.2010.12.1111 10.1016/j.annemergmed.2006.01.018 10.1016/j.jaci.2013.11.007 10.1016/S0140-6736(19)30420-9 10.1016/j.jaip.2019.06.037 10.1111/pai.13066 10.1056/NEJMoa1812856 10.1016/j.jaip.2019.01.022 10.1542/peds.2018-1235 10.1001/jamanetworkopen.2018.5630 |
| ContentType | Journal Article |
| Copyright | 2020 The Authors 2020 The Authors. 2020 The Authors 2020 |
| Copyright_xml | – notice: 2020 The Authors – notice: 2020 The Authors. – notice: 2020 The Authors 2020 |
| DBID | 6I. AAFTH AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.1016/j.waojou.2020.100455 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1939-4551 |
| ExternalDocumentID | oai_doaj_org_article_1b5d2cd3803f4e5e920a618382d601ca PMC7519204 10_1016_j_waojou_2020_100455 S1939455120303586 |
| GroupedDBID | --- .1- .FO 08G 0R~ 123 4.4 53G 5VS 7RV 7X7 8C1 8FI 8FJ AAEDW AAKAS AAKDD AALRI AAXUO AAYWO ABMAC ABUWG ACGFS ACIHN ACVFH ADBBV ADBIZ ADCNI ADRAZ ADUKV ADVLN ADZCM AEAQA AEUPX AEXQZ AFJKZ AFKRA AFPUW AFRHN AFTJW AFTRI AHBYD AHMBA AHSBF AHYZX AIGII AITUG AIZYK AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMKLP AMRAJ AOIJS APXCP AQUVI ASPBG AVWKF BCNDV BENPR BFQNJ BKEYQ BMC BPHCQ BVXVI C6C CCPQU CS3 EBS EJD EX3 FDB FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE HZ~ IAO IHR IPNFZ ITC KD2 KQ8 M0T M41 M48 M~E NAPCQ NTWIH O9- OK1 OVD P2P PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC RBZ RIG RNS ROL RPM RSV SOJ SSZ TEORI UKHRP V2I W3M WOQ WOW Z5R -A0 0SF 3V. 6I. AACTN AAFTH ABVAZ ACRMQ ADINQ AFGXO AFNRJ AWKKM C24 IHW NCXOZ AAYXX AFFHD CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c559t-db7d0dc30e40ad8d6a4bf4fe92072caddd9f8d71a068d3871240170494f8b8513 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 24 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000577463100010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1939-4551 |
| IngestDate | Fri Oct 03 12:30:35 EDT 2025 Tue Sep 30 17:00:38 EDT 2025 Fri Sep 05 06:53:15 EDT 2025 Wed Nov 05 20:59:22 EST 2025 Tue Nov 18 21:54:01 EST 2025 Fri Feb 23 02:44:26 EST 2024 Tue Oct 14 19:34:22 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | CF AF BOT Efficacy FAQOL Oral immunotherapy Quality of life AEs QoL PB TF Peanut allergy PF SAE Safety FA OIT PedsQL FAIM |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c559t-db7d0dc30e40ad8d6a4bf4fe92072caddd9f8d71a068d3871240170494f8b8513 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://doaj.org/article/1b5d2cd3803f4e5e920a618382d601ca |
| PMID | 33005286 |
| PQID | 2448402014 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_1b5d2cd3803f4e5e920a618382d601ca pubmedcentral_primary_oai_pubmedcentral_nih_gov_7519204 proquest_miscellaneous_2448402014 crossref_citationtrail_10_1016_j_waojou_2020_100455 crossref_primary_10_1016_j_waojou_2020_100455 elsevier_sciencedirect_doi_10_1016_j_waojou_2020_100455 elsevier_clinicalkey_doi_10_1016_j_waojou_2020_100455 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-08-01 |
| PublicationDateYYYYMMDD | 2020-08-01 |
| PublicationDate_xml | – month: 08 year: 2020 text: 2020-08-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationTitle | The World Allergy Organization journal |
| PublicationYear | 2020 |
| Publisher | Elsevier Inc World Allergy Organization Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: World Allergy Organization – name: Elsevier |
| References | (bib6) 2018 Soller, Abrams, Carr (bib30) 2019; 7 Bingemann, Herbert, Young (bib10) 2020; 8 Varshney, Jones, Scurlock (bib20) 2011; 127 Arasi, Caminiti, Crisafulli (bib24) 2019; 12 (bib12) 2020 (bib25) 2019 Loh, Tang (bib1) 2018; 15 Anagnostou, Islam, King (bib41) 2014; 383 Vickery, Vereda (bib16) 2018; 379 Cherkaoui, Ben-Shoshan, Alizadehfar (bib29) 2015; 5 Tang, Ponsonby, Orsini (bib42) 2015; 135 Blumchen, Ulbricht, Staden (bib37) 2010; 126 Gupta, Warren, Smith (bib2) 2019; 2 Cannon (bib4) 2018; 24 Wood (bib15) 2017; 27 Vickery, Berglund, Burk (bib22) 2017; 139 Ballmer-Weber (bib5) 2011; 81 Otani, Begin, Kearney (bib48) 2014; 10 Hsiao K-C, Ponsonby A-L, Axelrad C, et al. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial. The Lancet Child & Adolescent Health;1:97-105. Epstein-Rigbi, Goldberg, Levy, Nachshon, Elizur (bib33) 2019; 7 MacGinnitie, Rachid, Gragg (bib43) 2017; 139 Baumert, Taylor, Koppelman (bib17) 2018; 6 Chu, Wood, French (bib28) 2019; 393 Reier-Nilsen, Carlsen, Michelsen (bib34) 2019; 30 Dunn Galvin, McMahon, Ponsonby, Hsiao, Tang, Ps (bib31) 2018; 73 Gupta, Warren, Smith (bib3) 2018; 142 Nagakura, Sato, Yanagida (bib47) 2018; 175 Bird, Spergel, Jones (bib46) 2018 Mar-Apr; 6 Keet, Frischmeyer-Guerrerio, Thyagarajan (bib14) 2012; 129 Nurmatov, Dhami, Arasi (bib18) 2017; 72 Jones, Pons, Roberts (bib36) 2009; 124 Feng, Kim (bib11) 2019; 57 Sampson, Munoz-Furlong, Campbell (bib26) 2006; 47 Blumchen, Trendelenburg, Ahrens (bib19) 2019; 7 Muraro, Roberts, Clark (bib27) 2007; 62 Vickery, Scurlock, Kulis (bib40) 2014; 133 Hofmann, Scurlock, Jones (bib35) 2009; 124 Cox, Sicherer (bib8) 2015; 101 Chinthrajah, Purington, Andorf (bib21) 2019; 394 Kukkonen, Uotila, Malmberg, Pelkonen, Makela (bib44) 2017; 106 Schneider, Rachid, LeBovidge, Blood, Mittal, Umetsu (bib39) 2013; 132 Ebisawa, Ito, Fujisawa (bib9) 2017; 66 Muraro, Agache, Clark (bib32) 2014; 69 Anagnostou, Clark, King, Islam, Deighton, Ewan (bib38) 2011; 41 Howe, Leibowitz, Perry (bib23) 2019; 7 Cianferoni, Muraro (bib7) 2012; 32 Burbank, Sood, Vickery, Wood (bib13) 2016; 36 Reier-Nilsen (10.1016/j.waojou.2020.100455_bib34) 2019; 30 Cox (10.1016/j.waojou.2020.100455_bib8) 2015; 101 Epstein-Rigbi (10.1016/j.waojou.2020.100455_bib33) 2019; 7 Vickery (10.1016/j.waojou.2020.100455_bib22) 2017; 139 Bird (10.1016/j.waojou.2020.100455_bib46) 2018; 6 Bingemann (10.1016/j.waojou.2020.100455_bib10) 2020; 8 Gupta (10.1016/j.waojou.2020.100455_bib3) 2018; 142 Varshney (10.1016/j.waojou.2020.100455_bib20) 2011; 127 Chinthrajah (10.1016/j.waojou.2020.100455_bib21) 2019; 394 Ballmer-Weber (10.1016/j.waojou.2020.100455_bib5) 2011; 81 Muraro (10.1016/j.waojou.2020.100455_bib27) 2007; 62 Anagnostou (10.1016/j.waojou.2020.100455_bib41) 2014; 383 (10.1016/j.waojou.2020.100455_bib25) 2019 (10.1016/j.waojou.2020.100455_bib6) 2018 Howe (10.1016/j.waojou.2020.100455_bib23) 2019; 7 Ebisawa (10.1016/j.waojou.2020.100455_bib9) 2017; 66 Hofmann (10.1016/j.waojou.2020.100455_bib35) 2009; 124 Schneider (10.1016/j.waojou.2020.100455_bib39) 2013; 132 Kukkonen (10.1016/j.waojou.2020.100455_bib44) 2017; 106 10.1016/j.waojou.2020.100455_bib45 Blumchen (10.1016/j.waojou.2020.100455_bib19) 2019; 7 Baumert (10.1016/j.waojou.2020.100455_bib17) 2018; 6 MacGinnitie (10.1016/j.waojou.2020.100455_bib43) 2017; 139 Otani (10.1016/j.waojou.2020.100455_bib48) 2014; 10 Arasi (10.1016/j.waojou.2020.100455_bib24) 2019; 12 Loh (10.1016/j.waojou.2020.100455_bib1) 2018; 15 Gupta (10.1016/j.waojou.2020.100455_bib2) 2019; 2 Anagnostou (10.1016/j.waojou.2020.100455_bib38) 2011; 41 Dunn Galvin (10.1016/j.waojou.2020.100455_bib31) 2018; 73 Vickery (10.1016/j.waojou.2020.100455_bib40) 2014; 133 Muraro (10.1016/j.waojou.2020.100455_bib32) 2014; 69 Nurmatov (10.1016/j.waojou.2020.100455_bib18) 2017; 72 Tang (10.1016/j.waojou.2020.100455_bib42) 2015; 135 Cannon (10.1016/j.waojou.2020.100455_bib4) 2018; 24 Nagakura (10.1016/j.waojou.2020.100455_bib47) 2018; 175 Cianferoni (10.1016/j.waojou.2020.100455_bib7) 2012; 32 Wood (10.1016/j.waojou.2020.100455_bib15) 2017; 27 Jones (10.1016/j.waojou.2020.100455_bib36) 2009; 124 Blumchen (10.1016/j.waojou.2020.100455_bib37) 2010; 126 Vickery (10.1016/j.waojou.2020.100455_bib16) 2018; 379 Cherkaoui (10.1016/j.waojou.2020.100455_bib29) 2015; 5 Feng (10.1016/j.waojou.2020.100455_bib11) 2019; 57 Sampson (10.1016/j.waojou.2020.100455_bib26) 2006; 47 Soller (10.1016/j.waojou.2020.100455_bib30) 2019; 7 Keet (10.1016/j.waojou.2020.100455_bib14) 2012; 129 Burbank (10.1016/j.waojou.2020.100455_bib13) 2016; 36 Chu (10.1016/j.waojou.2020.100455_bib28) 2019; 393 |
| References_xml | – volume: 32 start-page: 165 year: 2012 end-page: 195 ident: bib7 article-title: Food-induced anaphylaxis publication-title: Immunol Allergy Clin – volume: 69 start-page: 1046 year: 2014 end-page: 1057 ident: bib32 article-title: EAACI food allergy and anaphylaxis guidelines: managing patients with food allergy in the community publication-title: Allergy – volume: 135 start-page: 737 year: 2015 end-page: 744 ident: bib42 article-title: Administration of a probiotic with peanut oral immunotherapy: a randomized trial publication-title: J Allergy Clin Immunol – volume: 393 start-page: 2222 year: 2019 end-page: 2232 ident: bib28 article-title: Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety publication-title: Lancet – volume: 5 start-page: 16 year: 2015 ident: bib29 article-title: Accidental exposures to peanut in a large cohort of Canadian children with peanut allergy publication-title: Clin Transl Allergy – volume: 7 start-page: 429 year: 2019 end-page: 436 ident: bib33 article-title: Quality of life of food-allergic patients before, during, and after oral immunotherapy publication-title: J Allergy Clin Immunol Pract – volume: 175 start-page: 181 year: 2018 end-page: 188 ident: bib47 article-title: Oral immunotherapy in Japanese children with anaphylactic peanut allergy publication-title: Int Arch Allergy Immunol – volume: 24 start-page: S428 year: 2018 end-page: S433 ident: bib4 article-title: The economic impact of peanut allergies publication-title: Am J Manag Care – volume: 81 start-page: 173 year: 2011 end-page: 180 ident: bib5 article-title: Allergic reactions to food proteins publication-title: Int J Vitam Nutr Res – year: 2019 ident: bib25 article-title: Allergenic Products Advisory Committee September 13, 2019 Meeting Announcement – volume: 2 year: 2019 ident: bib2 article-title: Prevalence and severity of food allergies among US adults publication-title: JAMA Netw Open – volume: 379 start-page: 1991 year: 2018 end-page: 2001 ident: bib16 article-title: AR101 oral immunotherapy for peanut allergy publication-title: N Engl J Med – volume: 142 year: 2018 ident: bib3 article-title: The public health impact of parent-reported childhood food allergies in the United States publication-title: Pediatrics – volume: 129 start-page: 448 year: 2012 end-page: 455 ident: bib14 article-title: The safety and efficacy of sublingual and oral immunotherapy for milk allergy publication-title: J Allergy Clin Immunol – volume: 8 start-page: 343 year: 2020 ident: bib10 article-title: Deficits and opportunities in allergists' approaches to food allergy-related bullying publication-title: J Allergy Clin Immunol Pract – volume: 124 start-page: 292 year: 2009 end-page: 300 ident: bib36 article-title: Clinical efficacy and immune regulation with peanut oral immunotherapy publication-title: J Allergy Clin Immunol – volume: 15 start-page: 2043 year: 2018 ident: bib1 article-title: The epidemiology of food allergy in the global context publication-title: Int J Environ Res Publ Health – volume: 106 start-page: 274 year: 2017 end-page: 281 ident: bib44 article-title: Double-blind placebo-controlled challenge showed that peanut oral immunotherapy was effective for severe allergy without negative effects on airway inflammation publication-title: Acta Paediatr – volume: 394 start-page: 1437 year: 2019 end-page: 1449 ident: bib21 article-title: Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study publication-title: Lancet – volume: 126 start-page: 83 year: 2010 end-page: 91 e81 ident: bib37 article-title: Oral peanut immunotherapy in children with peanut anaphylaxis publication-title: J Allergy Clin Immunol – volume: 139 start-page: 873 year: 2017 end-page: 881 ident: bib43 article-title: Omalizumab facilitates rapid oral desensitization for peanut allergy publication-title: J Allergy Clin Immunol – volume: 66 start-page: 248 year: 2017 end-page: 264 ident: bib9 article-title: Japanese guidelines for food allergy 2017 publication-title: Allergol Int – volume: 7 start-page: 479 year: 2019 end-page: 491 e410 ident: bib19 article-title: Efficacy, safety, and quality of life in a multicenter, randomized, placebo-controlled trial of low-dose peanut oral immunotherapy in children with peanut allergy publication-title: J Allergy Clin Immunol Pract – volume: 73 start-page: 560 year: 2018 end-page: 568 ident: bib31 article-title: The longitudinal impact of probiotic and peanut oral immunotherapy on health-related quality of life publication-title: Allergy – volume: 36 start-page: 55 year: 2016 end-page: 69 ident: bib13 article-title: Oral immunotherapy for food allergy publication-title: Immunol Allergy Clin – volume: 72 start-page: 1133 year: 2017 end-page: 1147 ident: bib18 article-title: Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis publication-title: Allergy – volume: 6 start-page: 457 year: 2018 end-page: 465 ident: bib17 article-title: Quantitative assessment of the safety benefits associated with increasing clinical peanut thresholds through immunotherapy publication-title: J Allergy Clin Immunol Pract – volume: 383 start-page: 1297 year: 2014 end-page: 1304 ident: bib41 article-title: Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial publication-title: Lancet – year: 2018 ident: bib6 publication-title: Blue Cross Blue Shield. Childhood Allergies in America – volume: 127 start-page: 654 year: 2011 end-page: 660 ident: bib20 article-title: A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response publication-title: J Allergy Clin Immunol – volume: 124 start-page: 286 year: 2009 end-page: 291 ident: bib35 article-title: Safety of a peanut oral immunotherapy protocol in children with peanut allergy publication-title: J Allergy Clin Immunol – volume: 10 start-page: 25 year: 2014 ident: bib48 article-title: Multiple-allergen oral immunotherapy improves quality of life in caregivers of food-allergic pediatric subjects publication-title: Allergy Asthma Clin Immunol – volume: 57 start-page: 74 year: 2019 end-page: 82 ident: bib11 article-title: Beyond avoidance: the psychosocial impact of food allergies publication-title: Clin Rev Allergy Immunol – volume: 7 start-page: 1550 year: 2019 end-page: 1559 ident: bib23 article-title: Changing patient mindsets about non-life-threatening symptoms during oral immunotherapy: a randomized clinical trial publication-title: J Allergy Clin Immunol Pract – volume: 132 start-page: 1368 year: 2013 end-page: 1374 ident: bib39 article-title: A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients publication-title: J Allergy Clin Immunol – volume: 6 start-page: 476 year: 2018 Mar-Apr end-page: 485 ident: bib46 article-title: Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial publication-title: J Allergy Clin Immunol Pract – volume: 139 start-page: 173 year: 2017 end-page: 181 e178 ident: bib22 article-title: Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective publication-title: J Allergy Clin Immunol – volume: 47 start-page: 373 year: 2006 end-page: 380 ident: bib26 article-title: Second symposium on the definition and management of anaphylaxis: summary report--second national Institute of allergy and infectious disease/food allergy and anaphylaxis network symposium publication-title: Ann Emerg Med – volume: 62 start-page: 857 year: 2007 end-page: 871 ident: bib27 article-title: The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology publication-title: Allergy – year: 2020 ident: bib12 article-title: Palforzia – volume: 7 start-page: 2759 year: 2019 end-page: 2767 ident: bib30 article-title: First real-world safety analysis of preschool peanut oral immunotherapy publication-title: J Allergy Clin Immunol Pract – volume: 41 start-page: 1273 year: 2011 end-page: 1281 ident: bib38 article-title: Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome publication-title: Clin Exp Allergy – volume: 101 start-page: 131 year: 2015 end-page: 144 ident: bib8 article-title: Peanut and tree nut allergy publication-title: Chem Immunol Allergy – volume: 27 start-page: 151 year: 2017 end-page: 159 ident: bib15 article-title: Oral immunotherapy for food allergy publication-title: J Investig Allergol Clin Immunol – reference: Hsiao K-C, Ponsonby A-L, Axelrad C, et al. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial. The Lancet Child & Adolescent Health;1:97-105. – volume: 12 start-page: 100010 year: 2019 ident: bib24 article-title: The safety of oral immunotherapy for food allergy during maintenance phase: effect of counselling on adverse reactions publication-title: World Allergy Organ J – volume: 30 start-page: 638 year: 2019 end-page: 645 ident: bib34 article-title: Parent and child perception of quality of life in a randomized controlled peanut oral immunotherapy trial publication-title: Pediatr Allergy Immunol – volume: 133 start-page: 468 year: 2014 end-page: 475 ident: bib40 article-title: Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy publication-title: J Allergy Clin Immunol – volume: 10 start-page: 25 year: 2014 ident: 10.1016/j.waojou.2020.100455_bib48 article-title: Multiple-allergen oral immunotherapy improves quality of life in caregivers of food-allergic pediatric subjects publication-title: Allergy Asthma Clin Immunol doi: 10.1186/1710-1492-10-25 – volume: 106 start-page: 274 year: 2017 ident: 10.1016/j.waojou.2020.100455_bib44 article-title: Double-blind placebo-controlled challenge showed that peanut oral immunotherapy was effective for severe allergy without negative effects on airway inflammation publication-title: Acta Paediatr doi: 10.1111/apa.13668 – volume: 135 start-page: 737 year: 2015 ident: 10.1016/j.waojou.2020.100455_bib42 article-title: Administration of a probiotic with peanut oral immunotherapy: a randomized trial publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2014.11.034 – volume: 15 start-page: 2043 year: 2018 ident: 10.1016/j.waojou.2020.100455_bib1 article-title: The epidemiology of food allergy in the global context publication-title: Int J Environ Res Publ Health doi: 10.3390/ijerph15092043 – volume: 36 start-page: 55 year: 2016 ident: 10.1016/j.waojou.2020.100455_bib13 article-title: Oral immunotherapy for food allergy publication-title: Immunol Allergy Clin – volume: 72 start-page: 1133 year: 2017 ident: 10.1016/j.waojou.2020.100455_bib18 article-title: Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis publication-title: Allergy doi: 10.1111/all.13124 – volume: 73 start-page: 560 year: 2018 ident: 10.1016/j.waojou.2020.100455_bib31 article-title: The longitudinal impact of probiotic and peanut oral immunotherapy on health-related quality of life publication-title: Allergy doi: 10.1111/all.13330 – volume: 41 start-page: 1273 year: 2011 ident: 10.1016/j.waojou.2020.100455_bib38 article-title: Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome publication-title: Clin Exp Allergy doi: 10.1111/j.1365-2222.2011.03699.x – volume: 6 start-page: 476 year: 2018 ident: 10.1016/j.waojou.2020.100455_bib46 article-title: Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2017.09.016 – volume: 101 start-page: 131 year: 2015 ident: 10.1016/j.waojou.2020.100455_bib8 article-title: Peanut and tree nut allergy publication-title: Chem Immunol Allergy doi: 10.1159/000375417 – volume: 24 start-page: S428 year: 2018 ident: 10.1016/j.waojou.2020.100455_bib4 article-title: The economic impact of peanut allergies publication-title: Am J Manag Care – volume: 7 start-page: 429 year: 2019 ident: 10.1016/j.waojou.2020.100455_bib33 article-title: Quality of life of food-allergic patients before, during, and after oral immunotherapy publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2018.06.016 – volume: 81 start-page: 173 year: 2011 ident: 10.1016/j.waojou.2020.100455_bib5 article-title: Allergic reactions to food proteins publication-title: Int J Vitam Nutr Res doi: 10.1024/0300-9831/a000055 – volume: 62 start-page: 857 year: 2007 ident: 10.1016/j.waojou.2020.100455_bib27 article-title: The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology publication-title: Allergy doi: 10.1111/j.1398-9995.2007.01421.x – volume: 5 start-page: 16 year: 2015 ident: 10.1016/j.waojou.2020.100455_bib29 article-title: Accidental exposures to peanut in a large cohort of Canadian children with peanut allergy publication-title: Clin Transl Allergy doi: 10.1186/s13601-015-0055-x – volume: 126 start-page: 83 year: 2010 ident: 10.1016/j.waojou.2020.100455_bib37 article-title: Oral peanut immunotherapy in children with peanut anaphylaxis publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2010.04.030 – volume: 139 start-page: 873 year: 2017 ident: 10.1016/j.waojou.2020.100455_bib43 article-title: Omalizumab facilitates rapid oral desensitization for peanut allergy publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2016.08.010 – volume: 175 start-page: 181 year: 2018 ident: 10.1016/j.waojou.2020.100455_bib47 article-title: Oral immunotherapy in Japanese children with anaphylactic peanut allergy publication-title: Int Arch Allergy Immunol doi: 10.1159/000486310 – volume: 57 start-page: 74 year: 2019 ident: 10.1016/j.waojou.2020.100455_bib11 article-title: Beyond avoidance: the psychosocial impact of food allergies publication-title: Clin Rev Allergy Immunol doi: 10.1007/s12016-018-8708-x – volume: 69 start-page: 1046 year: 2014 ident: 10.1016/j.waojou.2020.100455_bib32 article-title: EAACI food allergy and anaphylaxis guidelines: managing patients with food allergy in the community publication-title: Allergy doi: 10.1111/all.12441 – volume: 66 start-page: 248 year: 2017 ident: 10.1016/j.waojou.2020.100455_bib9 article-title: Japanese guidelines for food allergy 2017 publication-title: Allergol Int doi: 10.1016/j.alit.2017.02.001 – volume: 383 start-page: 1297 year: 2014 ident: 10.1016/j.waojou.2020.100455_bib41 article-title: Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(13)62301-6 – volume: 7 start-page: 2759 year: 2019 ident: 10.1016/j.waojou.2020.100455_bib30 article-title: First real-world safety analysis of preschool peanut oral immunotherapy publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2019.04.010 – volume: 132 start-page: 1368 year: 2013 ident: 10.1016/j.waojou.2020.100455_bib39 article-title: A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2013.09.046 – volume: 139 start-page: 173 year: 2017 ident: 10.1016/j.waojou.2020.100455_bib22 article-title: Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2016.05.027 – volume: 124 start-page: 286 year: 2009 ident: 10.1016/j.waojou.2020.100455_bib35 article-title: Safety of a peanut oral immunotherapy protocol in children with peanut allergy publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2009.03.045 – volume: 12 start-page: 100010 year: 2019 ident: 10.1016/j.waojou.2020.100455_bib24 article-title: The safety of oral immunotherapy for food allergy during maintenance phase: effect of counselling on adverse reactions publication-title: World Allergy Organ J doi: 10.1016/j.waojou.2018.11.008 – volume: 129 start-page: 448 year: 2012 ident: 10.1016/j.waojou.2020.100455_bib14 article-title: The safety and efficacy of sublingual and oral immunotherapy for milk allergy publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2011.10.023 – volume: 6 start-page: 457 year: 2018 ident: 10.1016/j.waojou.2020.100455_bib17 article-title: Quantitative assessment of the safety benefits associated with increasing clinical peanut thresholds through immunotherapy publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2017.05.006 – volume: 7 start-page: 479 year: 2019 ident: 10.1016/j.waojou.2020.100455_bib19 article-title: Efficacy, safety, and quality of life in a multicenter, randomized, placebo-controlled trial of low-dose peanut oral immunotherapy in children with peanut allergy publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2018.10.048 – volume: 32 start-page: 165 year: 2012 ident: 10.1016/j.waojou.2020.100455_bib7 article-title: Food-induced anaphylaxis publication-title: Immunol Allergy Clin – ident: 10.1016/j.waojou.2020.100455_bib45 doi: 10.1016/S2352-4642(17)30041-X – volume: 394 start-page: 1437 year: 2019 ident: 10.1016/j.waojou.2020.100455_bib21 article-title: Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study publication-title: Lancet doi: 10.1016/S0140-6736(19)31793-3 – year: 2019 ident: 10.1016/j.waojou.2020.100455_bib25 – volume: 124 start-page: 292 year: 2009 ident: 10.1016/j.waojou.2020.100455_bib36 article-title: Clinical efficacy and immune regulation with peanut oral immunotherapy publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2009.05.022 – volume: 27 start-page: 151 year: 2017 ident: 10.1016/j.waojou.2020.100455_bib15 article-title: Oral immunotherapy for food allergy publication-title: J Investig Allergol Clin Immunol doi: 10.18176/jiaci.0143 – volume: 127 start-page: 654 year: 2011 ident: 10.1016/j.waojou.2020.100455_bib20 article-title: A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2010.12.1111 – volume: 47 start-page: 373 year: 2006 ident: 10.1016/j.waojou.2020.100455_bib26 article-title: Second symposium on the definition and management of anaphylaxis: summary report--second national Institute of allergy and infectious disease/food allergy and anaphylaxis network symposium publication-title: Ann Emerg Med doi: 10.1016/j.annemergmed.2006.01.018 – volume: 133 start-page: 468 year: 2014 ident: 10.1016/j.waojou.2020.100455_bib40 article-title: Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2013.11.007 – volume: 393 start-page: 2222 year: 2019 ident: 10.1016/j.waojou.2020.100455_bib28 article-title: Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety publication-title: Lancet doi: 10.1016/S0140-6736(19)30420-9 – volume: 8 start-page: 343 year: 2020 ident: 10.1016/j.waojou.2020.100455_bib10 article-title: Deficits and opportunities in allergists' approaches to food allergy-related bullying publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2019.06.037 – year: 2018 ident: 10.1016/j.waojou.2020.100455_bib6 – volume: 30 start-page: 638 year: 2019 ident: 10.1016/j.waojou.2020.100455_bib34 article-title: Parent and child perception of quality of life in a randomized controlled peanut oral immunotherapy trial publication-title: Pediatr Allergy Immunol doi: 10.1111/pai.13066 – volume: 379 start-page: 1991 year: 2018 ident: 10.1016/j.waojou.2020.100455_bib16 article-title: AR101 oral immunotherapy for peanut allergy publication-title: N Engl J Med doi: 10.1056/NEJMoa1812856 – volume: 7 start-page: 1550 year: 2019 ident: 10.1016/j.waojou.2020.100455_bib23 article-title: Changing patient mindsets about non-life-threatening symptoms during oral immunotherapy: a randomized clinical trial publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2019.01.022 – volume: 142 year: 2018 ident: 10.1016/j.waojou.2020.100455_bib3 article-title: The public health impact of parent-reported childhood food allergies in the United States publication-title: Pediatrics doi: 10.1542/peds.2018-1235 – volume: 2 year: 2019 ident: 10.1016/j.waojou.2020.100455_bib2 article-title: Prevalence and severity of food allergies among US adults publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2018.5630 |
| SSID | ssj0060153 |
| Score | 2.309181 |
| SecondaryResourceType | review_article |
| Snippet | Food allergy (FA) is a growing public health problem with personal, social, nutritional, and economic consequences. In the United States, it is estimated that... |
| SourceID | doaj pubmedcentral proquest crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 100455 |
| SubjectTerms | Efficacy Oral immunotherapy Peanut allergy Quality of life Safety |
| Title | Oral immunotherapy for peanut allergy: The pro argument |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1939455120303586 https://dx.doi.org/10.1016/j.waojou.2020.100455 https://www.proquest.com/docview/2448402014 https://pubmed.ncbi.nlm.nih.gov/PMC7519204 https://doaj.org/article/1b5d2cd3803f4e5e920a618382d601ca |
| Volume | 13 |
| WOSCitedRecordID | wos000577463100010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central customDbUrl: eissn: 1939-4551 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0060153 issn: 1939-4551 databaseCode: RBZ dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: Directory of Open Access Journals customDbUrl: eissn: 1939-4551 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0060153 issn: 1939-4551 databaseCode: DOA dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1939-4551 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0060153 issn: 1939-4551 databaseCode: M~E dateStart: 20080101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV05T8MwFLYAIcSCOEW5ZCTWiBxu7bABasXANYDUzXJ8QBFKUQ8QC7-d9-ykaqYysGRI4sT5_Gx_L37vMyFnWnBmYAyI8pyDgyKUioAlJJFTBle9gKQaL-J6y-_vRb-fP85t9YUxYUEeOAB3nhRtk2qTiThzzLZtnsaqA3YoUgO-hPbUCFhP7UyFMRiueP1JYCd5xIAU1ElzPrLrSw2hocA3TH2QAMM0v7lJyWv3N-amOe7ZjJycm4p6m2Sj4pD0MtR9iyzZcpus3VWr5DuEP0AhOsDMjyq_6psCN6X41306obh7yujl-4KCiVB4J1Wjlyn-JNwlz73u0_VNVG2QEGlwBCaRKbiJjc5iy2JlhOkoVjjmECOeahi5TO6E4YmKOwIQ5DCXo1wOy5kTBVCtbI-slMPS7hMaK9cuRGpTi2FrHVeYxAD5cYJpobSxLZLVCEldqYfjJhbvsg4Te5MBV4m4yoBri0SzUh9BPWPB_VcI_uxe1L72J8AiZGURcpFFtEi7bjpZp5fCgAgPGix4OZ-Vq-hHoBV_KHlaW4iE3olLLqq0w-lYAnkS6KEnDJ7eMJ3GNzavlINXr_PNgV2nMTv4D1AOyTpWOIQuHpGVyWhqj8mq_pwMxqMTssz74sR3ITje_XR_AWbyH_E |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oral+immunotherapy+for+peanut+allergy%3A+The+pro+argument&rft.jtitle=The+World+Allergy+Organization+journal&rft.au=Chinthrajah%2C+R+Sharon&rft.au=Cao%2C+Shu&rft.au=Dunham%2C+Theresa&rft.au=Sampath%2C+Vanitha&rft.date=2020-08-01&rft.issn=1939-4551&rft.eissn=1939-4551&rft.volume=13&rft.issue=8&rft.spage=100455&rft_id=info:doi/10.1016%2Fj.waojou.2020.100455&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1939-4551&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1939-4551&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1939-4551&client=summon |